Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma

Jeng, Yung‐Ming; Wang, T.‐H.; Lu, Su-Hsi; Yuan, Ray-Hwang; Hsu, Hui‐Chun

doi:10.1002/bjs.6438

Cited by 26 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S1) according to published reports. (22,23) The staining results were evaluated by a pathologist (Y.M.J.) who was blind to the clinical background of the specimens.…”

Section: Methodsmentioning

confidence: 99%

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Chen

Jeng

Chang³

et al. 2011

Cancer Science

View full text Add to dashboard Cite

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported to enhance proliferation and invasion in various cancers. The role of IMP3 on neuroblastoma (NB) is unknown. We aimed to clarify the prognostic significance of IMP3 expression in patients with NB. By microarray analysis, high IMP3 expression was found in patients with poor outcome. IMP3 expression in 90 NB samples was analyzed by immunohistochemical staining to correlate with clinical stages, histology, and patient outcome. Positive IMP3 expression was detected in 52 of 90 patients, and was significantly correlated with undifferentiated histology, advanced stages, MYCN amplification, and poor outcome. In subgroups, positive IMP3 expression could predict an even worse prognosis in patients with advanced disease, with normal MYCN status, or with MYCN amplification (P = 0.005, P = 0.001, and P = 0.033, respectively). The IMP3 expression decreased by induction of differentiation with retinoid acid treatment in SK-N-DZ and SK-N-SH cells in vitro. The invasion ability of NB cells also decreased as IMP3 knockdown by using RNA interference in vitro. In summary, high expression of IMP3 in NB might contribute to the undifferentiated phenotype and invasive behaviors, leading to a poor prognosis. Determining IMP3 expression in NB could help to improve a personalized therapy. (Cancer Sci 2011; 102: 2191-2198 N euroblastoma (NB), a common cancer of early childhood that originates from primitive sympathetic neural precursors, has a remarkable heterogeneity of clinical behaviors ranging from spontaneous regression to rapid progression and death. Therapeutic options are proposed according to the Children's Oncology Group risk stratification criteria based on clinical and biological factors, including clinical stage, MYCN status, age at diagnosis, histology, and ploidy status.(1,2) Treatment strategy, which ranges from observation alone to intensive multimodal therapy, depends on the risk stratification of the patient in one of the three subgroups of low-, intermediate-, and high-risk of death. Although several biological and molecular prognostic factors have been identified, amplification of the MYCN oncogene, which occurs in roughly 20% of primary NB, is one of the most powerful prognostic factors in NB.(3) The co-opting neurotrophin pathways including the neurotrophin receptors (TrkA, TrkB, and TrkC) and their ligands (NGF, BDNF, and neurotrophin-3, respectively), which regulate the differentiation, apoptosis, and growth of neural cells, are also important prognosis-related factors in NB.(4) However, some patients with a normal MYCN copy number still present with clinically aggressive progression similar to those with MYCN-amplified tumors, suggesting that other unfavorable molecules determining inferior survival may exist.(5,6)The insulin-like growth factor II mRNA-binding protein 3 (IMP3), also known as L532S or K homology domain-containing protein overexpressed in cancer (KOC), is a member of the RNA-binding protein family that includes IMP1, IMP2...

show abstract

“…S1) according to published reports. (22,23) The staining results were evaluated by a pathologist (Y.M.J.) who was blind to the clinical background of the specimens.…”

Section: Methodsmentioning

confidence: 99%

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Chen

Jeng

Chang³

et al. 2011

Cancer Science

View full text Add to dashboard Cite

show abstract

“…Table 1 outlines the reported frequencies of IMP3 expression in human malignancies, either by immunohistochemistry or reverse transcription polymerase chain reaction (RT-PCR) studies. IMP3 is expressed in a variety of tumors with variable positivity, including pancreatic adenocarcinoma, esophageal adenocarcinoma, melanoma, gallbladder carcinoma, serous endometrial carcinoma, Hodgkin lymphoma, pulmonary and extrapulmonary small cell carcinoma, pulmonary large cell neuroendocrine carcinoma, Merkel cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, ovarian carcinoma, non-small cell lung cancer, follicular thyroid carcinoma, laryngeal squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma of the bladder, osteosarcoma, malignant pleural mesothelioma, meningioma, pituitary adenoma, and pituitary carcinoma [6,9,[11][12][13][14][15][16][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][39][40][41][42][43][44][45][46][47][48][49][50][51][52]…”

Section: Introductionmentioning

confidence: 99%

The use of insulin like-growth factor II messenger RNA binding protein–3 in diagnostic pathology

Findeis‐Hosey

2011

Human Pathology

View full text Add to dashboard Cite

“…High levels of IMP3 expression have been reported to have diagnostic and/or prognostic value in different malignant tumors (kidney, ovary, liver, endometrium, esophagus, biliary tract, bladder, uterine cervix, stomach, colonrectum, esophagus, lung, exocrine pancreas, thyroid, ovary, testis, bone, and skin) [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] (Table 2). Our results confirmed the expression of IMP3 in the normal pituitary tissues, previously reported, using immunohistochemical, Western blotting, and RT-PCR analyses.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have shown that IMP3 is associated with aggressive and advanced carcinomas in colon, kidney, neuroendocrine skin (Merkel cell carcinoma), liver, bladder, ovary, and in soft tissue sarcomas [16][17][18][19][20][21][22][23][24][25]. On the basis of these results, IMP3 may be a useful prognostic factor in many malignant solid tumors.…”

Section: Introductionmentioning

confidence: 97%

Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues

et al. 2009

View full text Add to dashboard Cite

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein highly expressed in fetal tissue and malignant tumors but rarely found in adult benign tissues. In various tumors, IMP3 expression is correlated with increased tumor aggressiveness and reduced overall survival. To our knowledge, IMP3 expression has not been investigated in pituitary tumors. We analyzed the immunohistochemical expression of IMP3 in five normal pituitary tissues and 75 pituitary tumors (64 adenomas and 11 carcinomas) to determine if specific tumor types expressed IMP3 and if there were differences in IMP3 expression between adenomas and carcinomas. Immunohistochemical analysis showed that IMP3 was positive in four (80%) normal pituitaries with focal stain in a subset of normal anterior pituitary cells. IMP3 was expressed in 31% (20/64) of adenomas and in 36% (4/11) of carcinomas. A slightly higher level of IMP3 expression was observed in PRL-GH-TSH adenomas compared to the other types of pituitary adenomas. Expression of IMP3 was not significantly higher in carcinomas than in adenomas (p = 0.737). RT-PCR and Western Blotting supported the heterogeneous expression of IMP3. These results indicate that IMP3 is expressed both in normal and in neoplastic pituitary gland tissues without significant differences in expression levels in pituitary carcinomas.

show abstract

Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma

Abstract: IMP-3 expression correlates with the metastatic potential of gastric adenocarcinoma and is an independent prognostic factor.

Cited by 26 publications

References 24 publications

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

The use of insulin like-growth factor II messenger RNA binding protein–3 in diagnostic pathology

Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues

Contact Info

Product

Resources

About